Reem A. Ghanem
Stanford University
2 Papers
Reem A. Ghanem is an academic researcher from Stanford University. The author has contributed to research in topics: Oligodendrocyte & Nicotinamide mononucleotide. The author has an hindex of 2, co-authored 2 publications.
Chat about Author
Papers
Loss of Adaptive Myelination Contributes to Methotrexate Chemotherapy-Related Cognitive Impairment
Anna Geraghty,Erin M. Gibson,Reem A. Ghanem,Jacob J. Greene,Alfonso Ocampo,Andrea K. Goldstein,Lijun Ni,Tao Yang,Rebecca M. Marton,Sergiu P. Paşca,Michael E. Greenberg,Frank M. Longo,Michelle Monje +12 more
TL;DR: It is demonstrated that remote MTX exposure blocks activity-regulated myelination, a molecular mechanism required for adaptive myelinations that is aberrant in CRCI due to microglial activation.
218
Therapeutic strategies for diffuse midline glioma from high-throughput combination drug screening
Grant L. Lin,Kelli M. Wilson,Michele Ceribelli,Benjamin Z. Stanton,Pamelyn Woo,Sara Kreimer,Elizabeth Y. Qin,Xiaohu Zhang,James Lennon,Surya Nagaraja,Patrick J. Morris,Michael Quezada,Shawn M. Gillespie,Damien Y. Duveau,Aleksandra M. Michalowski,Paul Shinn,Rajarshi Guha,Marc Ferrer,Carleen Klumpp-Thomas,Sam Michael,Crystal McKnight,Paras S. Minhas,Zina Itkin,Eric H. Raabe,Lu Chen,Reem A. Ghanem,Anna Geraghty,Lijun Ni,Katrin I. Andreasson,Nicholas A Vitanza,Katherine E. Warren,Craig J. Thomas,Michelle Monje +32 more
TL;DR: This study provides a comprehensive single-agent and combinatorial drug screen for DMG and identifies concomitant HDAC and proteasome inhibition as a promising therapeutic strategy that underscores underrecognized metabolic vulnerabilities in DMG.
216